AMRX today
$21.71+$0.33 (+1.54%)close Nov 11, 2026Trend
DailyUptrend (confirmed)
4 hourExpanding
1 hourStrong Bullish
15 minBearish
5 minStrong Bullish
Daily trend turns down below $18.79
Key levels
Resistance$24.35
Support$21.68
Support$20.28
Latest news & SEC filings
AnalystUBS lifts its valuation level for Amneal to $28
AnalystLeerink Partners keeps Outperform on Amneal Pharmaceuticals, lifts price target to $25
All AMRX news →About Amneal
Amneal is a drugmaker that creates, produces, and sells a wide range of medications. Its business has three parts: one supplies lower-cost copies of off-patent drugs, shots, and biologic copies; another sells branded treatments for brain and hormone-related conditions; and a third distributes medicines and health products to government bodies, shops, and care providers. It runs operations across North America, South Asia, and Europe.
Based on the company's 10-K filed Feb 27, 2026.
Nasdaq · Healthcare
Amneal Pharmaceuticals, Inc. (AMRX)
What Is the Price Target for AMRX?
SEPT Low Target
$20.00
SEPT Mid Target
$23.50
SEPT High Target
$27.00
Analyst Consensus
$23.50
Is AMRX a Buy or Sell Right Now?
Thesis
- •Revenue growing 8.1% YoY with STABLE trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AMRX.
Start Free Trial →Is AMRX Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$18.73
48
Moat Score
NARROW
7/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with AMRX?
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| BUCHI J KEVIN | director | Sale | 20,445 | - | Sep 17, 2026 |
| BUCHI J KEVIN | director | Buy | 20,445 | $295K | Sep 11, 2026 |
| BOYER ANDREW S | officer | Sale | 80,000 | - | Sep 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AMRX Growth Story
Revenue YoY
8.1%
3yr Revenue CAGR
10.9%
EPS Growth YoY
157.89%
FCF Growth YoY
11.0%
Revenue Trend
STABLE
Dark Pool Trades for AMRX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AMRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:25:45 | $21.71 | 9,091 | $$197K | BUY |
| 21:42:18 | $21.71 | 1,964 | $$43K | BUY |
| 21:00:37 | $21.71 | 1,200 | $$26K | BUY |
| 21:00:37 | $21.71 | 1,489 | $$32K | BUY |
| 21:00:37 | $21.71 | 1,234 | $$27K | BUY |
5 dark pool trades shown · $$325K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Amneal Pharmaceuticals, Inc. (AMRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AMRX — frequently asked questions
What is AMRX stock price today?
Amneal Pharmaceuticals, Inc. (AMRX) is at $21.71, up 1.54% (+$0.33) at the Nov 11, 2026 close.
Why is AMRX stock moving today?
Latest AMRX news — Nov 6, 2026: UBS lifts its valuation level for Amneal to $28 · Nov 5, 2026: Leerink Partners keeps Outperform on Amneal Pharmaceuticals, lifts price target to $25
What is the AMRX price target?
The average analyst price target for AMRX is $23.50, ranging from $20 to $27, based on 6 analysts. Latest: JP Morgan maintains on Oct 22, 2026.
What do analysts rate AMRX?
Analyst ratings for AMRX: 0 Buy, 8 Hold, 0 Sell — consensus Hold.
Did AMRX beat earnings?
AMRX last reported on Jul 30, 2026: EPS $0.30 vs $0.22 expected — a beat of 34.8%.
What is AMRX's P/E ratio?
AMRX trades at a P/E of 42.6 vs a Healthcare average of 17.6.
Does AMRX pay a dividend?
AMRX does not currently pay a dividend.
How much debt does AMRX have?
Amneal Pharmaceuticals, Inc. reported $2.6B of debt and $128M of cash (Jun 30, 2026).
What are AMRX support and resistance levels?
Support: $21.68, $20.28, $19.02. Resistance: $24.35.
What are insiders doing with AMRX?
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
What is the latest news on AMRX?
Nov 6, 2026: UBS lifts its valuation level for Amneal to $28 · Nov 5, 2026: Leerink Partners keeps Outperform on Amneal Pharmaceuticals, lifts price target to $25